In this discussion, experts review findings from a large real-world dataset comparing clinical outcomes of 2 frontline ...
High LAG3 RNA expression in metastatic RCC is associated with improved ORR but not significant OS benefit, indicating adaptive immune resistance. Tumors with high LAG3 levels show robust infiltration ...
The process of TIL therapy is complex and requires the coordination of multiple specialties at authorized treatment centers, ...
Osvyrti and Jubereq are FDA-approved denosumab biosimilars for osteoporosis and cancer-related skeletal events, ...
Zidesamtinib targets ROS1+ NSCLC patients with prior TKI treatment, addressing CNS-penetrant treatment challenges and ...
The second study presented at the SITC meeting focuses on a “next-generation” approach following TIL therapy, utilizing ...
High CD8-positive T cell infiltration is linked to shorter PFS in epithelial ovarian cancer patients treated with bevacizumab ...
During a live event, Hannah Choe, MD, discussed options for steroid-resistant cGVHD based on organ involvement, efficacy, and safety profiles. The management of steroid-refractory chronic ...
Safety concerns included a 58% rate of treatment-related adverse events, with severe cases like immune-related colitis and a grade 5 serious adverse event. A novel combination therapy shows promising ...
Neladalkib showed a 31% ORR in TKI-pretreated ALK+ NSCLC patients, with durable responses at 12 and 18 months.
The FDA has granted full approval to tarlatamab-dlle (Imdelltra) for the treatment of adult patients with extensive stage ...
The FDA has granted an accelerated approval to sevabertinib (Hyrnuo) for the treatment of adult patients with previously ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback